ArriVent BioPharma, Inc.
AVBP
$34.00
$0.180.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 59.14% | 58.02% | 41.74% | 44.90% | 48.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.73% | 88.25% | 73.30% | 72.07% | 68.98% |
| Operating Income | -11.73% | -88.25% | -73.30% | -72.07% | -68.98% |
| Income Before Tax | -14.10% | -106.87% | -86.52% | -82.93% | -70.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.10% | -106.87% | -86.52% | -82.93% | -70.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.10% | -106.87% | -86.52% | -82.93% | -70.91% |
| EBIT | -11.73% | -88.25% | -73.30% | -72.07% | -68.98% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 6.67% | -73.47% | 56.61% | 72.61% | 84.78% |
| Normalized Basic EPS | 6.78% | -73.31% | 56.56% | 72.61% | 84.78% |
| EPS Diluted | 6.67% | -73.47% | 56.61% | 72.61% | 84.78% |
| Normalized Diluted EPS | 6.78% | -73.31% | 56.56% | 72.61% | 84.78% |
| Average Basic Shares Outstanding | 22.44% | 22.18% | 52.39% | 113.25% | 316.14% |
| Average Diluted Shares Outstanding | 22.44% | 22.18% | 52.39% | 113.25% | 316.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |